ADA Reviewing Police Tussle; Obesity Trial Lawsuit; Retatrutide's Early Access
(MedPage Today) -- The American Diabetes Association (ADA) asked for patience as its Audit and Governance Committee reviews the incident at this year's annual meeting -- when five prominent experts were removed by police -- and prepares recommendations...
The American Diabetes Association is awaiting a review of a recent police incident from its annual meeting before issuing recommendations. Meanwhile, a phase III clinical trial found that once-weekly somapacitan was as effective as daily growth hormone injections at treating obesity in girls with Turner syndrome. Novo Nordisk is facing a shareholder lawsuit over its weight-loss drug CagriSema, claiming the company misled investors.
Plastic surgeons are seeing a rise in patients seeking treatment for changes in their facial structure after using GLP-1 agonists. Eli Lilly is expanding access to its experimental obesity medication retatrutide. The FDA approved a biosimilar to Novolog, a rapid-acting insulin. Nearly 500,000 Medicaid beneficiaries with diabetes could lose coverage by 2034 if policy does not intervene.
The FDA released new draft guidance for generic versions of diabetes and weight-loss drugs like semaglutide and tirzepatide. Transgender service members challenging a military ban are facing closed-door separation hearings. Actor Ethan Suplee warns about the potential effects of GLP-1 drugs after significant weight loss. Some women claim GLP-1 drugs aided in their ability to become pregnant.
Novo Nordisk's IL-6 inhibitor ziltivekimab did not reduce cardiovascular event risks in a phase III trial.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
